Mesoblast Ltd ADR MESO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MESO is a good fit for your portfolio.
News
-
Mesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L Application
-
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
-
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
-
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
-
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
-
Mesoblast Financial Results and Corporate Update Webcast
-
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
-
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
Trading Information
- Previous Close Price
- $6.00
- Day Range
- $5.82–6.24
- 52-Week Range
- $1.61–10.24
- Bid/Ask
- $6.17 / $6.24
- Market Cap
- $709.52 Mil
- Volume/Avg
- 198,867 / 2.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- 0.11
- Price/Sales
- 67.11
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 83
- Website
- https://www.mesoblast.com
Comparables
Valuation
|
Metric
|
MESO
|
ICVX
|
EWTX
|
|---|---|---|---|
Price/Earnings (Normalized) | 0.11 | — | — |
Price/Book Value | 1.19 | 3.30 | 3.33 |
Price/Sales | 67.11 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
MESO
ICVX
EWTX
Financial Strength
|
Metric
|
MESO
|
ICVX
|
EWTX
|
|---|---|---|---|
Quick Ratio | 2.59 | 17.59 | 18.98 |
Current Ratio | 2.71 | 18.06 | 19.50 |
Interest Coverage | −2.96 | — | — |
Quick Ratio
MESO
ICVX
EWTX
Profitability
|
Metric
|
MESO
|
ICVX
|
EWTX
|
|---|---|---|---|
Return on Assets (Normalized) | −11.71% | −29.30% | −24.36% |
Return on Equity (Normalized) | −15.62% | −31.87% | −25.87% |
Return on Invested Capital (Normalized) | −9.87% | −34.69% | −29.82% |
Return on Assets
MESO
ICVX
EWTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fbyyqdlhdl | Scrhl | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Swmsqdvf | Bwknzn | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pzkbgsvzx | Rqgnxg | $99.6 Bil | |
MRNA
| Moderna Inc | Qjpjjwz | Vyg | $38.8 Bil | |
ARGX
| argenx SE ADR | Rwdmhqqq | Xzjp | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Ysclmhzby | Frmy | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mhwjvpzt | Hgsmcp | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xyzllvqxs | Vnnsvkv | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hkvqxxyft | Phsgnky | $12.4 Bil | |
INCY
| Incyte Corp | Kxvcnkyq | Yfkdtf | $11.9 Bil |